共查询到20条相似文献,搜索用时 0 毫秒
1.
Landau WM Nelson DA Armon C Argoff CE Samuels J Backonja MM 《Neurology》2007,69(6):614; author reply 614-614; author reply 615
2.
Manchikanti L Boswell MV Giordano J Kaplan E 《Neurology》2007,69(11):1191; author reply 1191-1191; author reply 1192
3.
4.
5.
6.
Spielholz NI 《Neurology》2003,61(11):1628; author reply 1628
7.
8.
9.
Silber MH 《Neurology》2001,56(10):1421; author reply 1421-1421; author reply 1422
10.
11.
12.
Armon C Evans RW;Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology 《Neurology》2005,65(4):510-512
Review of the literature on prevention of post-lumbar puncture headaches (PLPHAs) since the publication of the original assessment in 2000 yielded one study comparing use of cutting to atraumatic needles in diagnostic lumbar punctures, providing Class I evidence in favor of the atraumatic needle. Taken in conjunction with data from most studies in the anesthesiology literature, the Therapeutics and Technology Assessment Subcommittee concluded that use of an atraumatic spinal needle in adult patient populations reduces the frequency of PLPHA (Level A recommendation). It affirmed a previous conclusion that smaller needle size is associated with reduced frequency of PLPHA (Level A recommendation). 相似文献
13.
Frohman EM Goodin DS Calabresi PA Corboy JR Coyle PK Filippi M Frank JA Galetta SL Grossman RI Hawker K Kachuck NJ Levin MC Phillips JT Racke MK Rivera VM Stuart WH;Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology 《Neurology》2003,61(5):602-611
Advancements in imaging technologies and newly evolving treatments offer the promise of more effective management strategies for MS. Until recently, confirmation of the diagnosis of MS has generally required the demonstration of clinical activity that is disseminated in both time and space. Nevertheless, with the advent of MRI techniques, occult disease activity can be demonstrated in 50 to 80% of patients at the time of the first clinical presentation. Prospective studies have shown that the presence of such lesions predicts future conversion to clinically definite (CD) MS. Indeed, in a young to middle-aged adult with a clinically isolated syndrome (CIS), once alternative diagnoses are excluded at baseline, the finding of three or more white matter lesions on a T2-weighted MRI scan (especially if one of these lesions is located in the periventricular region) is a very sensitive predictor (>80%) of the subsequent development of CDMS within the next 7 to 10 years. Moreover, the presence of two or more gadolinium (Gd)-enhancing lesions at baseline and the appearance of either new T2 lesions or new Gd enhancement on follow-up scans are also highly predictive of the subsequent development of CDMS in the near term. By contrast, normal results on MRI at the time of clinical presentation makes the future development of CDMS considerably less likely. 相似文献
14.
15.
16.
17.
18.
Poser CM 《Neurology》2000,54(6):1393; author reply 1394-1393; author reply 1395
19.
20.
Scott TF Frohman EM De Seze J Gronseth GS Weinshenker BG;Therapeutics Technology Assessment Subcommittee of American Academy of Neurology 《Neurology》2011,77(24):2128-2134
OBJECTIVE: To assess the evidence for diagnostic tests and therapies for transverse myelitis (TM) and make evidence-based recommendations. METHODS: A review of the published literature from 1966 to March 2009 was performed, with evidence-based classification of relevant articles. Recommendations: Level B recommendations: neuromyelitis optica (NMO)-immunoglobulin G (IgG) antibodies should be considered useful to determine TM cause in patients presenting with clinical acute complete transverse myelitis (ACTM) features. The presence of NMO-IgG antibodies (aquaporin-4-specific antibodies) should be considered useful in determining increased TM recurrence risk. Level C recommendations: in suspected TM, distinction between ACTM or acute partial transverse myelitis may be considered useful to determine TM etiology and risk for relapse (more common with APTM). Age and gender may be considered useful to determine etiology in patients presenting with TM syndrome, with spinal infarcts seen more often in older patients and more female than male patients having TM due to multiple sclerosis (MS). Brain MRI characteristics consistent with those of MS may be considered useful to predict conversion to MS after a first partial TM episode. Longer spinal lesions extending over >3 vertebral segments may be considered useful in determining NMO vs MS. CSF examination for cells and oligoclonal bands may be considered useful to determine the cause of the TM syndrome. Plasma exchange may be considered in patients with TM who fail to improve after corticosteroid treatment. Rituximab may be considered in patients with TM due to NMO to decrease the number of relapses. Level U recommendations: there is insufficient evidence to support or refute the efficacy of other TM therapies or the usefulness of ethnicity to determine the cause of a subacute myelopathy. 相似文献